PnTx4(6-1), henceforth renamed δ-Ctenitoxin-Pn1a (δ-CNTX-Pn1a), a peptide from Phoneutria nigriventer spider venom, initially described as an insect toxin, binds to site 3 of sodium channels in nerve cord synaptosomes and slows down sodium current inactivation in isolated axons in cockroaches (Periplaneta americana). δ-CNTX-Pn1a does not cause any apparent toxicity to mice, when intracerebroventricularly injected (30 µg). In this study, we evaluated the antinociceptive effect of δ-CNTX-Pn1a in three animal pain models and investigated its mechanism of action in acute pain.
Introduction
The word pain derives from the Latin poena, which means "penalty" [1] , and treating pain has always been a challenge to mankind since ancient times. Nowadays, the International Association for the Study of Pain describes it as "an unpleasant sensory and emotional experience associated with real or potential tissue damage". Further understanding on the mechanisms by which pain signals are interpreted, transmitted and maintained will improve pain treatment strategies. antinociception when peripherally tested in rats [38] , this work aims at looking for the putative antinociceptive effect of δ-CNTX-Pn1a in different experimental pain models in rats: inflammatory, neuropathic and nociceptive. After confirming the antinociceptive effect of δ-CNTX-Pn1a in all these pain models, we proceeded to investigate the mechanisms underlying its analgesic properties, revealing the involvement of endogenous opioid and cannabinoid systems.
Results

Effect of δ-CNTX-Pn1a on Carrageenan-Induced Inflammatory Hyperalgesia
Administration of 5 µg of δ-CNTX-Pn1a, 2 h and 30 min after carrageenan (Cg), significantly increased the nociceptive threshold following carrageenan-induced inflammation. However, the administration of δ-CNTX-Pn1a by 30 min or 1 h and 30 min after Cg did not reverse hyperalgesia ( Figure 1 ). antinociception when peripherally tested in rats [38] , this work aims at looking for the putative antinociceptive effect of δ-CNTX-Pn1a in different experimental pain models in rats: inflammatory, neuropathic and nociceptive. After confirming the antinociceptive effect of δ-CNTX-Pn1a in all these pain models, we proceeded to investigate the mechanisms underlying its analgesic properties, revealing the involvement of endogenous opioid and cannabinoid systems.
Results
Effect of δ-CNTX-Pn1a on Carrageenan-Induced Inflammatory Hyperalgesia
Administration of 5 μg of δ-CNTX-Pn1a, 2 h and 30 min after carrageenan (Cg), significantly increased the nociceptive threshold following carrageenan-induced inflammation. However, the administration of δ-CNTX-Pn1a by 30 min or 1 h and 30 min after Cg did not reverse hyperalgesia ( Figure 1 ). Figure 1 . δ-CNTX-Pn1a antinociceptive effect following carrageenan-induced hyperalgesia. Rats were injected with 250 μg of carrageenan (Cg) into the right hind paw and then 5 μg of δ-CNTX-Pn1a (1 nmol) was intraplantarly administered into the same site, at different times (−30 min, 30 min, 1 h and 30 min, and 2 h and 30 min related to Cg injection). Nociceptive threshold was measured hourly 1 h after Cg injection. Each symbol represents MEAN ± SEM. n = 4 rats per group. Data were analyzed using ANOVA and Bonferroni post-test. p < 0.05 compared to Cg + Saline (*).
Effect of δ-CNTX-Pn1a on Neuropathic Hyperalgesia
Intrathecal administration of 0.5 μg of δ-CNTX-Pn1a reversed the hyperalgesia induced by surgical sciatic nerve constriction. The analgesic effect was observed 5 min after administration and this effect progressively decreased with time, not being detected after 20 min ( Figure 2 ).
Effect of δ-CNTX-Pn1a on Prostaglandin E2-Induced Hyperalgesia and Comparison between δ-CNTX-Pn1a and ω-Conotoxina MVIIA Antinociceptive Activity
PGE2 is known to decrease the nociceptive threshold of nociceptors, exerting a critical role in the generation and maintenance of nociception [42] . We investigated the effect of δ-CNTX-Pn1a on PGE2induced hyperalgesia and showed that this peptide increased, in a dose-dependent manner, the nociceptive threshold of rats. The highest tested dose (2 μg) induced a potent antinociception, which persisted for 30 min. This effect was less durable for the other tested doses (0.5 and 1 μg) ( Figure 3 ). . δ-CNTX-Pn1a antinociceptive effect following carrageenan-induced hyperalgesia. Rats were injected with 250 µg of carrageenan (Cg) into the right hind paw and then 5 µg of δ-CNTX-Pn1a (1 nmol) was intraplantarly administered into the same site, at different times (´30 min, 30 min, 1 h and 30 min, and 2 h and 30 min related to Cg injection). Nociceptive threshold was measured hourly 1 h after Cg injection. Each symbol represents MEAN˘SEM. n = 4 rats per group. Data were analyzed using ANOVA and Bonferroni post-test. p < 0.05 compared to Cg + Saline (*).
Effect of δ-CNTX-Pn1a on Neuropathic Hyperalgesia
Intrathecal administration of 0.5 µg of δ-CNTX-Pn1a reversed the hyperalgesia induced by surgical sciatic nerve constriction. The analgesic effect was observed 5 min after administration and this effect progressively decreased with time, not being detected after 20 min ( Figure 2 ).
Effect of δ-CNTX-Pn1a on Prostaglandin E 2 -Induced Hyperalgesia and Comparison between δ-CNTX-Pn1a
and ω-Conotoxina MVIIA Antinociceptive Activity PGE 2 is known to decrease the nociceptive threshold of nociceptors, exerting a critical role in the generation and maintenance of nociception [42] . We investigated the effect of δ-CNTX-Pn1a on PGE 2 -induced hyperalgesia and showed that this peptide increased, in a dose-dependent manner, the nociceptive threshold of rats. The highest tested dose (2 µg) induced a potent antinociception, which persisted for 30 min. This effect was less durable for the other tested doses (0.5 and 1 µg) ( Figure 3 ). The antinociceptive effect produced by 0.5 μg (minimum effective dose) of δ-CNTX-Pn1a was compared to the antinociceptive effect of ω-conotoxin MVIIA on PGE2-induced hyperalgesia. The peptide (0.5 μg) was intrathecally administered and the nociceptive threshold was measured 5 min after the administration. The antinociceptive effect was similar for both peptides (Figure 4 ). The antinociceptive effect produced by 0.5 μg (minimum effective dose) of δ-CNTX-Pn1a was compared to the antinociceptive effect of ω-conotoxin MVIIA on PGE2-induced hyperalgesia. The peptide (0.5 μg) was intrathecally administered and the nociceptive threshold was measured 5 min after the administration. The antinociceptive effect was similar for both peptides (Figure 4 ). The antinociceptive effect produced by 0.5 µg (minimum effective dose) of δ-CNTX-Pn1a was compared to the antinociceptive effect of ω-conotoxin MVIIA on PGE 2 -induced hyperalgesia. The peptide (0.5 µg) was intrathecally administered and the nociceptive threshold was measured 5 min after the administration. The antinociceptive effect was similar for both peptides (Figure 4 ). 
Involvement of Cannabinoid and Opioid Systems in δ-CNTX-Pn1a Antinociceptive Effect
The mechanism underlying δ-CNTX-Pn1a effect on the hyperalgesia induced by the inflammatory mediator PGE2 was also investigated. For this, we verified the possible effect of δ-CNTX-Pn1a on the cannabinoid and opioid pathways. In order to investigate the involvement of the cannabinoid system, animals were treated with AM251 (40, 80, 160 and 320 μg), a selective CB1 receptor antagonist, or AM630 (100 μg), a selective CB2 receptor antagonist, both administered 10 min before the peptide. AM251 reversed, in a dose-dependent manner, the antinociceptive effect of δ-CNTX-Pn1a, intrathecally administered (i.t.), on PGE2-induced hyperalgesia (Figure 5a ). On the other hand, 100 μg of AM630 showed no significant effect on δ-CNTX-Pn1a antinociceptive effect ( Figure  5b ). 
The mechanism underlying δ-CNTX-Pn1a effect on the hyperalgesia induced by the inflammatory mediator PGE 2 was also investigated. For this, we verified the possible effect of δ-CNTX-Pn1a on the cannabinoid and opioid pathways. In order to investigate the involvement of the cannabinoid system, animals were treated with AM251 (40, 80, 160 and 320 µg), a selective CB 1 receptor antagonist, or AM630 (100 µg), a selective CB 2 receptor antagonist, both administered 10 min before the peptide. AM251 reversed, in a dose-dependent manner, the antinociceptive effect of δ-CNTX-Pn1a, intrathecally administered (i.t.), on PGE 2 -induced hyperalgesia (Figure 5a ). On the other hand, 100 µg of AM630 showed no significant effect on δ-CNTX-Pn1a antinociceptive effect (Figure 5b) . 
The mechanism underlying δ-CNTX-Pn1a effect on the hyperalgesia induced by the inflammatory mediator PGE2 was also investigated. For this, we verified the possible effect of δ-CNTX-Pn1a on the cannabinoid and opioid pathways. In order to investigate the involvement of the cannabinoid system, animals were treated with AM251 (40, 80, 160 and 320 μg), a selective CB1 receptor antagonist, or AM630 (100 μg), a selective CB2 receptor antagonist, both administered 10 min before the peptide. AM251 reversed, in a dose-dependent manner, the antinociceptive effect of δ-CNTX-Pn1a, intrathecally administered (i.t.), on PGE2-induced hyperalgesia (Figure 5a ). On the other hand, 100 μg of AM630 showed no significant effect on δ-CNTX-Pn1a antinociceptive effect ( Figure  5b ). In order to explore the involvement of the opioid system, animals were treated with opioid receptor antagonists. The non-selective opioid antagonist, naloxone, reversed the antinociceptive effect of δ-CNTX-Pn1a (Figure 6a ). Selective antagonists for µ (Clocinamox) and δ (Naltrindole) receptors significantly decreased δ-CNTX-Pn1a antinociception (Figure 6b,c) . The selective antagonist for κ receptor (Nor-BNI) showed no significant effect on δ-CNTX-Pn1a antinociception (Figure 6d ).
In order to explore the involvement of the opioid system, animals were treated with opioid receptor antagonists. The non-selective opioid antagonist, naloxone, reversed the antinociceptive effect of δ-CNTX-Pn1a (Figure 6a ). Selective antagonists for μ (Clocinamox) and δ (Naltrindole) receptors significantly decreased δ-CNTX-Pn1a antinociception (Figure 6b and 6c) . The selective antagonist for κ receptor (Nor-BNI) showed no significant effect on δ-CNTX-Pn1a antinociception (Figure 6d ). 
Discussion
The antinociceptive potential of animal toxins has been subject of several investigations that demonstrate the antinociceptive effect of venoms and many of their derivative peptides [5, 6, 12, [43] [44] [45] [46] . Our results show the analgesic effect of δ-CNTX-Pn1a in inflammatory, neuropathic and nociceptive in vivo pain models. Moreover, we reveal that the antinociceptive effect of δ-CNTX-Pn1a in the nociceptive pain model involves both opioid and cannabinoid endogenous systems.
Intraplantar administration of δ-CNTX-Pn1a inhibited inflammatory pain only when administered 2 h and 30 min after carrageenan injection. This effect may be related to the kinetics of mediators release in carrageenan-induced inflammation. In fact, many mediators are involved in carrageenan inflammation, including histamine, serotonin, kinins and prostaglandins [47] . The 
Intraplantar administration of δ-CNTX-Pn1a inhibited inflammatory pain only when administered 2 h and 30 min after carrageenan injection. This effect may be related to the kinetics of mediators release in carrageenan-induced inflammation. In fact, many mediators are involved in carrageenan inflammation, including histamine, serotonin, kinins and prostaglandins [47] . The mediators involved in this nociceptive effect are most likely prostaglandins, which are known to decrease the threshold of nociceptor activation two hours after carrageenan administration [48] .
The pharmacological treatment of neuropathic pain remains a challenge. Indeed, the current pharmacological clinical management of neuropathic pain achieves clinically significant pain relief in less than 50% of patients [49] . Here, we tested δ-CNTX-Pn1a in the neuropathic pain model and found that this peptide reversed the hyperalgesia caused by sciatic constriction. The effect of δ-CNTX-Pn1a was significant up to 10 min after injection, decreasing progressively over time, and losing effect after 20 min.
According to Dalmolin and co-authors [46] and Oliveira and co-authors [50] , two peptides isolated from the venom of Phoneutria nigriventer induce marked antinociceptive effect in an experimental model of neuropathic pain. Both peptides are able to modulate voltage-sensitive calcium channels: Tx3-3 (ω-ctenitoxin-Pn2a) blocks P/Q and R types, while Tx3-5 (U 7 -ctenitoxin-Pn1a) is a selective and potent blocker of L type. In low doses (3-300 fmol/site), Tx3-5 (U 7 -ctenitoxin-Pn1a) was able to produce antinociception in postoperative, neuropathic and cancer-related pain models. The analgesic potential of these toxins isolated from Phoneutria nigriventer venom seems evident. However, future studies using different concentrations of δ-CNTX-Pn1a may reveal better toxin-induced reversal of the hyperalgesia in our neuropathic model.
It is known that loss of spinal opioid receptors and increased activity of physiological opioid antagonist systems occur in neuropathic pain. In contrast, no biologically relevant decrease in the number of CB 1 receptors was evident after dorsal injury [49] . Although we did not investigate the mechanism of action of δ-CNTX-Pn1a in the neuropathic pain model, the effect of the peptide on CB 1 receptors, observed for the nociceptive pain model discussed below, may encourage future investigations regarding a possible relationship between these receptors and the peptide analgesia observed in our neuropathic pain model.
When intrathecally administered, δ-CNTX-Pn1a showed a dose-dependent analgesic effect in PGE 2 -induced hyperalgesia. This effect was comparable to the antinociceptive effect of ω-conotoxin MVIIA, a peptide purified from the venom of the snail Conus magus. However, these two peptides apparently have distinct mechanisms of action. Indeed, the synthetic version of ω-conotoxin MVIIA is a powerful analgesic drug (Prialt ® , Dublin, Ireland) that has a unique mechanism of action involving potent and selective blockage of N-type calcium channels [16] . On the other hand, the mechanism underlying the analgesic effect of δ-CNTX-Pn1a involves both cannabinoid and opioid receptors. It is well known that these receptors are involved in antinociceptive pathways. However, there are few studies regarding the effect of animal toxins on these receptors. Here, we show that only AM251, a selective CB 1 receptor antagonist, when intrathecally administered, antagonizes the antinociceptive effect of δ-CNTX-Pn1a in PGE 2 -induced hyperalgesia (Figure 5a ). Using naloxone, a nonselective opioid receptor antagonist, the antinociceptive effect of δ-CNTX-Pn1a was reverted (Figure 6a ). In addition, we show that µ and δ opioid, but not κ receptors, are involved in δ-CNTX-Pn1a antinociception (Figure 6b,c) . Pnpp19, a peptide synthetized by our group, in addition to potentiating erectile function in rats, showed antinocieptive activity against PGE 2 hyperalgesia through activation of µ and δ opioid, and CB 1 cannabinoid receptors. This peptide also seems to be able to indirectly induce antinociception through inhibition of a neuronal endopeptidase responsible for the cleavage of the endogenous opioid peptide encephalin [22] . Different from these findings, Crotalphine peptide reduced PGE 2 -induced hyperalgesia through an increased activation of both κ-opioid and CB 2 cannabinoid receptors, being this effect mediated by dynorphin A [20] . This result reinforces the interaction between cannabinoid and opioid systems, as observed in our work and highlights the complexity of the nociceoptitive pathways.
Finally, we recently showed that rPnTx4(5-5) (rΓ-ctenitoxin-Pn1a), another insect toxin from P. nigriventer showing 63% of similarity to δ-CNTX-Pn1a, obtained by heterologous expression in E. coli, besides strongly slowing down the inactivation of Bg Na v (a sodium channel from Blatella germanica cockroach) also inhibited sodium currents on all tested Na v s from mammals (Na v 1.2 to Na v 1.6). It is worth noting that rΓ-ctenitoxin-Pn1a, as observed for δ-CNTX-Pn1a, did not show any apparent toxicity to mice, when i.c.v. injected (up to 30 µg). rΓ-ctenitoxin-Pn1a caused the highest current inhibition on Na v 1.3 (38. 43%˘8.04%, IC 50 = 1.5 µM) [35] . In addition to Na v 1.3, some subtypes of Na v s, especially Na v s 1.7, l.8 and 1.9, have been described to play a significant role in pain processes. However, in order to investigate if the antinociceptive effect of these insect-toxins involves the inhibition of sodium channels, other assays are required, including the test of its effects on Na v s 1.7, 1.8 and 1.9, which are critically involved in pain mechanisms. Another possible target of these toxins, as observed for rΓ-ctenitoxin-Pn1a [38, 39] is the NMDA receptor, which could also be involved in the observed antinociceptive effects. Other studies are in progress to try to clarify this point.
Conclusions
In the present study, we reveal that δ-CNTX-Pn1a, a peptide isolated from the venom of Phoneutria nigriventer spider and previously characterized as an insect toxin, shows a clear analgesic effect in three different in vivo pain models. Moreover, we show, for the first time, the involvement of CB 1 cannabinoid receptor and µ and δ opioid receptors in the antinociceptive effect of δ-CNTX-Pn1a. Taken together, our results may contribute for the development of novel therapeutic agents of a wide spectrum to manage pain, although studies are still necessary to better clarify the mechanisms involved in the effects of δ-CNTX-Pn1a.
Material and Methods
Animals
Male adult Wistar rats weighing 180-200 g were kept in a home cage environment with free access to water and food. Room temperature was maintained at 22˘2˝C with a 12-12 h light-dark cycle (lights on at 6:00 a.m.). Animals were acclimatized and familiarized with the experimental room for at least 1 day before testing. All experiments were carried out according to the current guidelines for the care of laboratory animals and ethical guidelines for investigations of experimental pain in conscious animals [51] , and were approved by the Ethics Committee on Animal Experimentation of the Federal University of Minas Gerais (protocol number: 102/2012 from 4 July 2012).
Drugs
The following drugs and chemicals were used: δ-CNTX-Pn1a was purified by a combination of preparative reverse phase HPLC (RP-HPLC), ion exchange HPLC and analytical reverse phase HPLC as previously described [52] . µ-Conotoxin MVIIA was purchased from Latoxan (Valence, France). Carrageenan (Sigma, St Louis, MO, USA), Prostaglandin E 2 (Enzo Life Sciences, Farmingdale, NY, USA), AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3carboxamide; Tocris, Pittsburg, PA, USA), AM630 (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol -3-yl(4-ethoxyphenyl) methanone Tocris, Pittsburgh, PA, USA), Naloxone (Sigma, St. Louis, MO, USA), Clocinnamox (Tocris, Pittsburgh, PA, USA), Naltrindole (Tocris, Pittsburgh, PA, USA), Nor-BNI (Nor-Binaltorphimine dihydrochloride; Sigma, St. Louis, MO, USA) were dissolved as follows: PGE 2 (2% ethanol in saline); AM251 and AM630 (12% DMSO in saline); Carrageenan, δ-CNTX-Pn1a, µ-Conotoxin MVIIA (MVIIA), Naloxone, Clocinnamox, Naltrindole and Nor-BNI (saline).
Drug Treatments
δ-CNTX-Pn1a (0.25-2 µg/site), MVIIA (0.25 µg/site), AM251 (40-320 µg/site), AM630 (100 µg/site), Naloxone (25-100 µg/site), Clocinnamox (20-80 µg/site), Naltrindole (30-120 µg/site) and Nor-BNI (50 µg/site) were administered through intrathecal (i.t.) route, according to Mestre and co-authors [53] . The i.t. injections were delivered in a volume of 20 µL/site per rat. δ-CNTX-Pn1a (5 µg/site), Carrageenan (250 µg/site) and Prostaglandin E 2 (2 µg/site) were administered through intraplantar route (ipl.) in a volume of 50 or 100 µL.
Carrageenan-Induced Inflammatory Hyperalgesia
Male rats received a 100-µL intradermal injection of carrageenan (2.5 mg/mL in isotonic saline) into the right hind paw. δ-CNTX-Pn1a (5 µg/site) was administered through intraplantar route in different times after Cg injection. The nociceptive threshold was evaluated before and hourly after δ-CNTX-Pn1a administration.
Prostaglandin E 2 -Induced Nociceptive Hyperalgesia
Male rats received a 100 µL intradermal injection of PGE 2 (0.02 mg/mL of PGE 2 , stored in ethanol, diluted in isotonic saline) into the right hind paw. δ-CNTX-Pn1a (0.25, 0.5, 1, 2 µg/site) was intrathecaly administered 2 h and 55 min after PGE 2 injection. The nociceptive threshold was evaluated after δ-CNTX-Pn1a administration, every ten minutes.
Nociceptive Test
The nociceptive threshold was measured according to the rat paw pressure test described by Randall and Selitto [54] . We used an analgesimeter (Ugo Basile, Varese, Italy) with a cone-shaped paw presser with a rounded tip, which applies a linearly increasing force to the rat's hind paw. The weight (g) required to elicit a nociceptive response (paw flexion) was determined as being the nociceptive threshold. A cutoff value of 300 g was used to minimize damage to the paws. The nociceptive threshold was measured in the right paw and determined as the average of three consecutive trials recorded before and various times after injection of the hyperalgesic agents. The same nociceptive thresholds were measured by two different experimenters.
Induction of Neuropathy
For the induction of peripheral neuropathy, male rats were first anesthetized (60 mg/kg of ketamine plus 9 mg/kg of xylazine hydrochloride, intramuscular). Then, a partial constriction of the right sciatic nerve was performed using a previously described procedure [55] . In sham-operated rats, the control group, the nerve was only exposed without any ligation. Fourteen days after the surgical procedure the mechanical sensitivity was measured and, if the neuropathic pain effectiveness was established, the tests were performed. Rats not submitted to surgical intervention and not treated were labeled as naive. In this model of pain, δ-CNTX-Pn1a (0.5 µg/site) was intrathecaly administered [53] .
Statistical Analysis
Data were analyzed for statistical significance by one-way ANOVA analysis of variance followed by Bonferroni's test. The minimum level of significance considered was p < 0.05. All graphics and analyses were performed using Prisma 5.0. (GraphPad Software Inc, San Diego, CA, USA).
